PE20160665A1 - Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x - Google Patents
Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid xInfo
- Publication number
- PE20160665A1 PE20160665A1 PE2015002397A PE2015002397A PE20160665A1 PE 20160665 A1 PE20160665 A1 PE 20160665A1 PE 2015002397 A PE2015002397 A PE 2015002397A PE 2015002397 A PE2015002397 A PE 2015002397A PE 20160665 A1 PE20160665 A1 PE 20160665A1
- Authority
- PE
- Peru
- Prior art keywords
- receptor
- farnesoid
- conjugates
- modulators
- amino acids
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 239000003613 bile acid Substances 0.000 title abstract 2
- 102100038495 Bile acid receptor Human genes 0.000 title 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS 11-HIDROXILO DE ACIDOS BILIARES DE FORMULA (I) O UN CONJUGADO DE AMINOACIDO FARMACEUTICAMENTE ACEPTABLE DEL MISMO DONDE R1 ES HIDROXILO; R2, R3, R4, R5 Y R6 SON TAL COMO SE DEFINEN EN LA DESCRIPCION. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR X FERNESOIDE (FXR) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, HEPATICA CRONICA, METABOLICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823169P | 2013-05-14 | 2013-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160665A1 true PE20160665A1 (es) | 2016-08-07 |
Family
ID=50721801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015002397A PE20160665A1 (es) | 2013-05-14 | 2014-05-14 | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x |
Country Status (38)
| Country | Link |
|---|---|
| US (7) | US9611289B2 (es) |
| EP (4) | EP3360881B1 (es) |
| JP (2) | JP6326131B2 (es) |
| KR (1) | KR102229952B1 (es) |
| CN (2) | CN105377870B (es) |
| AU (1) | AU2014267324B2 (es) |
| BR (1) | BR112015028399B1 (es) |
| CA (1) | CA2912139C (es) |
| CL (2) | CL2015003344A1 (es) |
| CR (1) | CR20150643A (es) |
| CY (1) | CY1122614T1 (es) |
| DK (4) | DK3360881T3 (es) |
| EA (1) | EA030152B1 (es) |
| ES (4) | ES2936638T3 (es) |
| GT (1) | GT201500324A (es) |
| HK (2) | HK1253326A1 (es) |
| HR (1) | HRP20180931T1 (es) |
| HU (1) | HUE037996T2 (es) |
| IL (2) | IL242555B (es) |
| LT (1) | LT2997035T (es) |
| MA (1) | MA38647B1 (es) |
| ME (1) | ME03082B (es) |
| MX (1) | MX352065B (es) |
| MY (1) | MY187886A (es) |
| NI (1) | NI201500160A (es) |
| PE (1) | PE20160665A1 (es) |
| PH (1) | PH12015502576B1 (es) |
| PL (3) | PL2997035T3 (es) |
| PT (3) | PT3360882T (es) |
| RS (1) | RS57372B1 (es) |
| SA (1) | SA515370140B1 (es) |
| SG (1) | SG11201509352XA (es) |
| SI (3) | SI3360882T1 (es) |
| SM (1) | SMT201800326T1 (es) |
| TN (1) | TN2015000497A1 (es) |
| TR (1) | TR201809041T4 (es) |
| UA (1) | UA118673C2 (es) |
| WO (1) | WO2014184271A1 (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440680C (en) | 2001-03-12 | 2010-06-01 | Roberto Pellicciari | Steroids as agonists for fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| PL2997035T3 (pl) | 2013-05-14 | 2018-10-31 | Intercept Pharmaceuticals, Inc. | 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| FI3626725T3 (fi) | 2014-05-29 | 2023-03-16 | Bar Pharmaceuticals S R L | Kolaanijohdannaisia käytettäväksi FXR:n ja TGR5:n/GPBAR1:n välittämien sairauksien hoidossa ja/tai ennaltaehkäisyssä |
| AU2015343025A1 (en) | 2014-11-06 | 2017-06-08 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an FXR/TGR5 agonists and methods of use thereof |
| JP6735748B2 (ja) | 2014-11-19 | 2020-08-05 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−３，７−ジオン−ステロイド |
| JP6698085B2 (ja) | 2014-11-19 | 2020-05-27 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド |
| CA2968301C (en) | 2014-11-19 | 2023-05-16 | NZP UK Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| KR102526631B1 (ko) | 2014-11-19 | 2023-04-27 | 엔제트피 유케이 리미티드 | 스테로이드 fxr 조절인자를 제조하기 위한 중간체로서의 6-알킬-7-하이드록시-4-엔-3-온 스테로이드 |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| MX2017006833A (es) | 2014-11-26 | 2018-02-13 | Enanta Pharm Inc | Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| MA41094A (fr) * | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
| US11311557B2 (en) * | 2015-02-06 | 2022-04-26 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| AU2016219266A1 (en) | 2015-02-11 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| SG11201707328SA (en) * | 2015-03-09 | 2017-10-30 | Intercept Pharmaceuticals Inc | Methods for modulating bone density |
| US11072630B2 (en) | 2015-03-10 | 2021-07-27 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| AU2016233579A1 (en) * | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| RS62110B1 (sr) | 2015-03-31 | 2021-08-31 | Enanta Pharm Inc | Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe |
| BR112017021311A2 (pt) * | 2015-04-07 | 2018-06-26 | Intercept Pharmaceuticals Inc | composições farmacêuticas para terapia de combinação |
| WO2016168553A1 (en) * | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Deuterated obeticholic acid |
| PE20180690A1 (es) | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| CN106478759A (zh) * | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| WO2017053428A1 (en) | 2015-09-21 | 2017-03-30 | Intercept Pharmaceuticals, Inc. | Methods of promoting hepatic regeneration |
| IL258359B2 (en) * | 2015-10-07 | 2023-11-01 | Intercept Pharmaceuticals Inc | Paranoid X receptor modulators. |
| SG11201806348PA (en) * | 2016-01-28 | 2018-08-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Steroid derivative fxr agonist |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| WO2017147174A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| ES2874682T3 (es) * | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| WO2017180577A1 (en) * | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating cancer |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| AU2017284160B2 (en) | 2016-06-13 | 2019-12-19 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| KR102499441B1 (ko) | 2016-11-29 | 2023-02-13 | 이난타 파마슈티칼스, 인코포레이티드 | 술포닐우레아 담즙산 유도체의 제조 방법 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| ES2959842T3 (es) | 2017-02-21 | 2024-02-28 | Genfit | Combinación de un agonista de PPAR con un agonista de FXR |
| AU2018225255A1 (en) * | 2017-02-23 | 2019-09-05 | Intercept Pharmaceuticals, Inc | Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof |
| KR102743630B1 (ko) | 2017-03-28 | 2024-12-18 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| WO2018226724A1 (en) * | 2017-06-05 | 2018-12-13 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of diabetic eye diseases with a bile acid derivatives |
| CA3067219A1 (en) * | 2017-06-23 | 2018-12-27 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of bile acid derivatives |
| KR20200031145A (ko) | 2017-07-24 | 2020-03-23 | 인터셉트 파마슈티컬즈, 인크. | 동위원소 표지된 담즙산 유도체 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN109182451B (zh) * | 2018-08-21 | 2021-06-11 | 四川大学 | 细胞色素cyp3a7酶的新型特异性探针反应及其应用 |
| SG11202107434PA (en) | 2019-01-15 | 2021-08-30 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| KR20220016146A (ko) | 2019-05-30 | 2022-02-08 | 인터셉트 파마슈티컬즈, 인크. | 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물 |
| JP7597787B2 (ja) | 2019-07-18 | 2024-12-10 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
| CN110540955B (zh) * | 2019-08-28 | 2021-09-17 | 北京协同创新研究院 | 一种提高分化细胞中nrob2基因表达量的方法 |
| ES3014367T3 (en) | 2020-01-15 | 2025-04-22 | Inst Nat Sante Rech Med | Use of fxr agonists for treating an infection by hepatitis d virus |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| WO2022233398A1 (en) * | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080775A (en) * | 1934-08-22 | 1937-05-18 | Celanese Corp | Shedding mechanism for circular looms |
| US2802775A (en) * | 1953-05-29 | 1957-08-13 | Merck & Co Inc | 11 alpha-hydroxylation of steroids by aspergillus ochraceus |
| JPS59205396A (ja) * | 1983-05-09 | 1984-11-20 | Kuraray Co Ltd | １１β−ヒドロキシプレグナ−４−エン−３−オン−２０−カルブアルデヒド及びその製造法 |
| JP2002532729A (ja) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| ITMI20021532A1 (it) * | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| US9498484B2 (en) * | 2004-03-12 | 2016-11-22 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| SI2040713T1 (sl) * | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals, Inc. | Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR |
| PL2997035T3 (pl) | 2013-05-14 | 2018-10-31 | Intercept Pharmaceuticals, Inc. | 11-hydroksy-6-podstawione pochodne kwasów żółciowych i ich koniugaty aminokwasowe jako modulatory receptorów farnezoidu x |
-
2014
- 2014-05-14 PL PL14723820T patent/PL2997035T3/pl unknown
- 2014-05-14 PT PT181636234T patent/PT3360882T/pt unknown
- 2014-05-14 EP EP18163622.6A patent/EP3360881B1/en active Active
- 2014-05-14 HU HUE14723820A patent/HUE037996T2/hu unknown
- 2014-05-14 ES ES20211780T patent/ES2936638T3/es active Active
- 2014-05-14 PT PT181636226T patent/PT3360881T/pt unknown
- 2014-05-14 UA UAA201511098A patent/UA118673C2/uk unknown
- 2014-05-14 MX MX2015015730A patent/MX352065B/es active IP Right Grant
- 2014-05-14 BR BR112015028399-3A patent/BR112015028399B1/pt active IP Right Grant
- 2014-05-14 RS RS20180690A patent/RS57372B1/sr unknown
- 2014-05-14 AU AU2014267324A patent/AU2014267324B2/en active Active
- 2014-05-14 PT PT147238208T patent/PT2997035T/pt unknown
- 2014-05-14 DK DK18163622.6T patent/DK3360881T3/da active
- 2014-05-14 SM SM20180326T patent/SMT201800326T1/it unknown
- 2014-05-14 TR TR2018/09041T patent/TR201809041T4/tr unknown
- 2014-05-14 ES ES14723820.8T patent/ES2671427T3/es active Active
- 2014-05-14 EP EP14723820.8A patent/EP2997035B8/en active Active
- 2014-05-14 DK DK14723820.8T patent/DK2997035T3/en active
- 2014-05-14 ES ES18163623T patent/ES2843737T3/es active Active
- 2014-05-14 TN TN2015000497A patent/TN2015000497A1/en unknown
- 2014-05-14 US US14/120,366 patent/US9611289B2/en active Active
- 2014-05-14 SG SG11201509352XA patent/SG11201509352XA/en unknown
- 2014-05-14 DK DK20211780.0T patent/DK3848038T3/da active
- 2014-05-14 MY MYPI2015002734A patent/MY187886A/en unknown
- 2014-05-14 KR KR1020157034951A patent/KR102229952B1/ko active Active
- 2014-05-14 JP JP2016513357A patent/JP6326131B2/ja active Active
- 2014-05-14 SI SI201431741T patent/SI3360882T1/sl unknown
- 2014-05-14 MA MA38647A patent/MA38647B1/fr unknown
- 2014-05-14 EP EP20211780.0A patent/EP3848038B1/en active Active
- 2014-05-14 DK DK18163623.4T patent/DK3360882T3/da active
- 2014-05-14 ME MEP-2018-159A patent/ME03082B/me unknown
- 2014-05-14 EP EP18163623.4A patent/EP3360882B1/en active Active
- 2014-05-14 CA CA2912139A patent/CA2912139C/en active Active
- 2014-05-14 LT LTEP14723820.8T patent/LT2997035T/lt unknown
- 2014-05-14 ES ES18163622T patent/ES2847002T3/es active Active
- 2014-05-14 PL PL18163622T patent/PL3360881T3/pl unknown
- 2014-05-14 PE PE2015002397A patent/PE20160665A1/es unknown
- 2014-05-14 SI SI201431742T patent/SI3360881T1/sl unknown
- 2014-05-14 SI SI201430701T patent/SI2997035T1/sl unknown
- 2014-05-14 EA EA201592055A patent/EA030152B1/ru unknown
- 2014-05-14 WO PCT/EP2014/059896 patent/WO2014184271A1/en active Application Filing
- 2014-05-14 PL PL18163623T patent/PL3360882T3/pl unknown
- 2014-05-14 CN CN201480036949.5A patent/CN105377870B/zh active Active
- 2014-05-14 CN CN201810162562.4A patent/CN108245523B/zh not_active Expired - Fee Related
-
2015
- 2015-11-12 IL IL242555A patent/IL242555B/en active IP Right Grant
- 2015-11-12 SA SA515370140A patent/SA515370140B1/ar unknown
- 2015-11-13 NI NI201500160A patent/NI201500160A/es unknown
- 2015-11-13 GT GT201500324A patent/GT201500324A/es unknown
- 2015-11-13 CL CL2015003344A patent/CL2015003344A1/es unknown
- 2015-11-13 PH PH12015502576A patent/PH12015502576B1/en unknown
- 2015-12-07 CR CR20150643A patent/CR20150643A/es unknown
-
2016
- 2016-07-15 CL CL2016001809A patent/CL2016001809A1/es unknown
- 2016-08-15 HK HK18112619.6A patent/HK1253326A1/zh unknown
- 2016-08-15 HK HK16109719.3A patent/HK1221471A1/zh unknown
-
2017
- 2017-02-16 US US15/434,685 patent/US20170216316A1/en not_active Abandoned
-
2018
- 2018-04-13 JP JP2018077654A patent/JP2018127481A/ja not_active Withdrawn
- 2018-06-01 CY CY20181100583T patent/CY1122614T1/el unknown
- 2018-06-15 HR HRP20180931TT patent/HRP20180931T1/hr unknown
- 2018-09-06 US US16/124,139 patent/US10532061B2/en active Active
-
2019
- 2019-11-26 US US16/695,528 patent/US11000532B2/en active Active
-
2020
- 2020-02-17 IL IL272718A patent/IL272718B/en active IP Right Grant
-
2021
- 2021-04-13 US US17/228,819 patent/US20210228599A1/en not_active Abandoned
-
2023
- 2023-04-03 US US18/295,091 patent/US20230233581A1/en not_active Abandoned
-
2024
- 2024-08-12 US US18/800,808 patent/US20240398834A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160665A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| MX2020003532A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos. | |
| CY1122500T1 (el) | Φαρμακευτικη συνθεση που περιεχει παραγωγα γλουταριμιδιου, και εφαρμογη αυτης για την αγωγη ηωσινοφιλικων νοσων | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| AR110299A1 (es) | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico | |
| CR11826A (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| UY33606A (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| BR112015008564A2 (pt) | derivados de 6-aminoindol como antagonistas de canal trp |